Effect of radioiodine treatment for Graves’ disease on the generation of TSH anti-receptor stimulating antibodies (TSI)
Radioiodine therapy leads to an increase in TSI, which can remain elevated for up to 12 months in more than half of GD patients. These findings suggest potential benefits of measuring TSI for guiding management decisions, particularly regarding antithyroid drug discontinuation and pregnancy planning.
Authors
- Cleber Camacho (ORCID: https://orcid.org/0000-0002-8653-0031)
- Teresa S. Kasamatsu
- Marcelo C. Batista (ORCID: https://orcid.org/0000-0002-9860-5408)
- Rui M. B. Maciel (ORCID: https://orcid.org/0000-0002-6123-6098)
- Lia B. Fiorin
- Carlos Ernesto Santos Ferreira (ORCID: https://orcid.org/0000-0003-2397-5866)
- João Roberto Maciel Martins (ORCID: https://orcid.org/0000-0002-0204-3552)
- Gilberto K. Furuzawa
- Carolina Castro Porto Silva Janovsky (ORCID: https://orcid.org/0000-0001-9383-7907)
- Reinaldo P. Furlanetto
- Luiza K. Matsumura
- Mario Luiz Vieira Castiglioni
- Melissa Furlaneto
Institutions
- Hospital Israelita Albert Einstein (BR)
- Universidade Nove de Julho (BR)
- Centro Paulista de Investigação Clinica (BR)
- Associação Paulista de Medicina (BR)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Archives of Endocrinology and Metabolism
- Published
- 2025-01-01
- DOI
- https://doi.org/10.20945/2359-4292-2025-0085
- Primary Topic
- Thyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Siemens Healthineers